Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 889.90 million, a decrease of 19.20% compared to RMB 1,101.36 million in the same period last year[19]. - Net profit attributable to shareholders for the first half of 2023 was approximately RMB 104.92 million, an increase of 21.48% from RMB 86.37 million in the previous year[19]. - The net profit after deducting non-recurring gains and losses was approximately RMB 95.61 million, up 19.63% from RMB 79.92 million in the same period last year[19]. - Basic earnings per share for the first half of 2023 were RMB 0.78, representing a 20.00% increase from RMB 0.65 in the same period last year[19]. - Diluted earnings per share for the first half of 2023 were RMB 0.77, an increase of 20.31% from RMB 0.64 in the previous year[19]. - The company reported a total comprehensive income of 54,380.62 million RMB for the first half of 2023, reflecting a significant increase compared to the previous period[179]. - The net profit attributable to shareholders for the first half of 2023 was 95,658.44 million, showing a growth of 6.10% compared to the previous year[172]. Cash Flow and Assets - The net cash flow from operating activities increased by 66.67% to approximately RMB 164.08 million, compared to RMB 98.45 million in the previous year[19]. - The company's cash and cash equivalents at the end of the period were 1.22 billion RMB, accounting for 36.89% of total assets, a decrease of 8.10% from the previous year[54]. - The company's cash and cash equivalents as of June 30, 2023, are 1,222,105,262.83 yuan, down from 1,329,776,484.49 yuan at the end of 2022[137]. - The total current assets decreased from 2,270,578,335.21 yuan to 2,023,612,212.08 yuan[137]. - The total assets of the company at the end of the first half of 2023 were reported at 3,941,290.0 million, compared to 3,776,170.3 million at the end of the previous year, marking a growth of approximately 4.36%[169]. - The total assets of the company reached 3,896,930 million, demonstrating growth in asset base[161]. Investment and Expansion - The company has established over 1,000 offline stores in China and maintains a presence on major e-commerce platforms such as Tmall, JD.com, and Douyin[40]. - The company aims to provide a healthy and fashionable lifestyle for global users, aligning with its vision of serving millions of families[28]. - The company plans to adjust its product strategy and implement proactive sales policies to boost overseas orders in response to varying market conditions[46]. - The company is actively developing new products in collaboration with ODM partners and expanding its market presence beyond Korea to other regions[81]. - The company plans to expand its market presence and invest in new product development to drive future growth[147]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[171]. Research and Development - The company completed 9 R&D projects and obtained 6 new invention patents, 51 utility model patents, and 11 design patents during the reporting period[48]. - The company aims to enhance its research and development efforts to innovate and improve product offerings[162]. - The company has initiated research and development for new technologies aimed at enhancing operational efficiency and customer engagement[171]. Market Trends and Strategies - The global massage equipment market is projected to reach approximately $23.6 billion by 2026, driven by increasing health awareness and disposable income in China[27]. - The domestic market shows a strong trend in consumer spending on massage and health care products, with significant growth in both domestic and international orders[41]. - The company employs an order-based production model, ensuring efficient management of manufacturing processes[38]. - The company utilizes a dual sales model for domestic and international markets, with a focus on ODM for global brands[34]. - The massage equipment industry is characterized by rapid technological advancements, integrating various high-tech fields[27]. Financial Management and Risks - The company faces risks from raw material price fluctuations, as over 80% of its cost structure is attributed to raw materials, which could impact net profit growth if prices rise significantly[79]. - The company has a significant reliance on BODYFRIEND, with its sales contributing a substantial portion of revenue; any adverse changes in this relationship could negatively affect performance[80]. - The company is managing foreign exchange risks through various strategies, including settling contracts in RMB and using hedging tools[83]. - The company emphasizes a diversified procurement strategy to mitigate risks associated with raw material shortages[39]. Shareholder and Stock Information - The total number of shareholders reached 12,065 by the end of the reporting period[115]. - The company has 138,973,433 unrestricted circulating shares, accounting for 99.29% of total shares[109]. - The top ten shareholders hold a total of 100,000,000 shares, with Lin Qi holding 34,900,230 shares (25.11%) and Lin Guangrong holding 21,499,870 shares (15.47%) [117]. - The company has approved a foreign exchange derivative trading limit of up to USD 300 million, with a current position accounting for 13.20% of this limit[68]. - The company announced the repurchase and cancellation of 1,000,000 restricted stock units due to unmet performance conditions in the 2021 incentive plan[90]. Legal and Compliance - The company is currently involved in a lawsuit with a claim for economic damages of 99 million yuan related to patent infringement on massage chairs, with the case still pending judgment[105]. - The company’s revenue recognition and accounting policies are in accordance with the relevant enterprise accounting standards, ensuring accurate financial reporting[190].

关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 08 月 08 日（星期二）至 08 月 14 日（星期一）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 Public@rotai.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 上海荣泰健康科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 8 日 发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年 半年度经营成果、财务状况，公司计划于 2023 年 08 月 15 日上午 10:00-11:00 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 | 证券代码：603579 | 证券简称：荣泰健康 公告编号：2023-046 | | --- | --- | | 转债代码：113606 | ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥385,718,637.33, representing a decrease of 31.71% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥37,501,251.13, down 35.70% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,866,712.47, a decline of 39.52% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.28, reflecting a decrease of 36.36% year-over-year[6] - The diluted earnings per share for Q1 2023 was also ¥0.28, down 33.33% from the same period last year[6] - Total operating revenue for Q1 2023 was CNY 385.72 million, a decrease of 31.7% compared to CNY 564.80 million in Q1 2022[19] - Net profit for Q1 2023 was CNY 37.68 million, a decline of 35.6% from CNY 58.56 million in Q1 2022[20] - Basic earnings per share for Q1 2023 were CNY 0.28, compared to CNY 0.44 in Q1 2022[21] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,259,730,630.27, down 4.79% from the end of the previous year[6] - Total assets as of Q1 2023 were CNY 3.26 billion, a decrease from CNY 3.42 billion at the end of Q1 2022[16] - Total liabilities as of Q1 2023 were CNY 1.35 billion, down from CNY 1.55 billion in Q1 2022[16] - Shareholders' equity attributable to the parent company was ¥1,903,618,815.29, an increase of 2.01% compared to the end of the previous year[6] - Shareholders' equity as of Q1 2023 was CNY 1.91 billion, an increase from CNY 1.87 billion in Q1 2022[17] Cash Flow - The company reported a net cash flow from operating activities of ¥21,078,065.76 for Q1 2023, with no applicable year-over-year comparison[5] - The net cash flow from operating activities for Q1 2023 was 21,078,065.76, a significant improvement from -27,415,890.24 in Q1 2022, indicating a recovery in operational efficiency[24] - Total cash inflow from operating activities was 448,101,157.18, while cash outflow was 427,023,091.42, resulting in a net cash inflow of 21,078,065.76 for the quarter[24] - Cash received from sales of goods and services in Q1 2023 was CNY 392.97 million, down 33.2% from CNY 589.07 million in Q1 2022[23] - The total cash and cash equivalents at the end of Q1 2023 were 1,242,747,863.10, down from 1,284,376,555.91 at the end of Q1 2022[25] Investments and Expenses - Research and development expenses for Q1 2023 were CNY 17.23 million, a decrease of 31.5% from CNY 25.17 million in Q1 2022[19] - Financial expenses for Q1 2023 were CNY 5.39 million, compared to CNY 4.86 million in Q1 2022[20] - Cash inflow from investment activities was 237,989,336.56, compared to 612,494,044.13 in the previous year, reflecting a decrease in investment returns[25] - The cash outflow for investment activities was 194,998,606.79, down from 542,435,408.90 in Q1 2022, suggesting a reduction in capital expenditures[25] Legal Matters - The company is currently involved in a legal dispute with a claim for economic damages of RMB 99 million related to patent infringement, which is still pending court judgment[13] - The company has taken proactive measures to respond to the ongoing litigation and is contesting the claims made against it[13] - The company has not provided specific guidance for future performance in this report, but it is actively monitoring market conditions and legal developments[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,229[10] - The company reported a total of 3,348,479 shares held in its repurchase account, accounting for 2.39% of the total shares as of March 31, 2023[12] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 1.99%, a decrease of 1.24 percentage points compared to the end of the previous year[6] - As of March 31, 2023, the company's cash and cash equivalents amounted to RMB 1,242,747,863.10, a decrease from RMB 1,329,776,484.49 as of December 31, 2022, representing a decline of approximately 6.5%[14] - The total current assets as of March 31, 2023, were RMB 2,038,128,218.89, down from RMB 2,270,578,335.21 at the end of 2022, indicating a decrease of about 10.2%[15] - The company's accounts receivable increased to RMB 106,227,100.14 from RMB 95,069,521.56, reflecting a growth of approximately 11.4%[15] - The inventory level decreased to RMB 177,040,326.87 from RMB 205,227,948.56, showing a reduction of around 13.7%[15] - Long-term equity investments were reported at RMB 58,586,718.35, slightly down from RMB 59,082,899.43, indicating a decrease of about 0.8%[15] - The total non-current assets as of March 31, 2023, were RMB 1,221,602,411.38, an increase from RMB 1,153,246,826.81 at the end of 2022, representing a growth of approximately 5.9%[15]

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2023-027 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于召开 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 05 月 08 日（星期一）至 05 月 12 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 Public@rotai.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 三、参加人员 总经理、董事：林琪先生 上海荣泰健康科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2023 年第一季度报告，为便于广大投资者更全面深入地了解公司 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 05 月 15 日上午 09:00- 10:00 举行 2023 年第一季度业绩说明会， ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2023-024 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 04 月 18 日（星期二）下午 13:00-14:00 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 04 月 11 日（星期二）至 04 月 17 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 Public@rotai.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海荣泰健康科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 7 日 发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 04 月 18 ...

2022年年度报告 公司代码：603579 公司简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 荣泰，更专业的按摩椅 上海荣泰健康科技股份有限公司 2022 年年度报告 ...

2022 年第三季度报告 证券代码：603579 证券简称：荣泰健康 上海荣泰健康科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | 项目 | 本报告期 | 本报告期 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 460,877,983.10 | -25.26 | 1,562,236,538.61 | -16.24 | | 归属于上市公司股东的 | 39,299,476.20 | -18.52 | 125,666,979.14 | -33.37 | | 净利润 | | | | | | 归属于上市公司股东的 ...

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 1,101,358,555.51, a decrease of 11.78% compared to RMB 1,248,377,561.46 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was RMB 86,367,502.94, down 38.47% from RMB 140,366,552.96 in the previous year[21]. - The net cash flow from operating activities decreased by 47.64%, amounting to RMB 98,446,913.62 compared to RMB 188,022,479.97 in the same period last year[21]. - Basic earnings per share for the first half of 2022 were RMB 0.65, a decline of 36.89% from RMB 1.03 in the same period last year[22]. - The weighted average return on equity decreased to 4.78%, down 3.48 percentage points from 8.26% in the previous year[22]. - The company reported a decrease of 28.37% in net profit after deducting non-recurring gains and losses, totaling RMB 79,921,203.93 compared to RMB 111,575,789.90 in the previous year[21]. - The company reported a significant increase in management expenses by 35.69% due to increased share-based payments compared to the previous year[65]. - The total comprehensive income for the first half of 2022 was CNY 85,488,588.12, a decrease of 38.4% from CNY 138,829,336.35 in the first half of 2021[144]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 3,300,276,316.39, an increase of 0.68% from RMB 3,277,932,920.71 at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were RMB 1,774,162,416.72, a slight decrease of 0.12% from RMB 1,776,370,370.24 at the end of the previous year[21]. - Cash and cash equivalents at the end of the period reached ¥1,161,888,674.51, representing 35.21% of total assets, an increase of 4.75% year-over-year[68]. - Accounts receivable amounted to ¥147,652,941.81, accounting for 4.47% of total assets, with a year-over-year increase of 3.50%[68]. - Inventory decreased to ¥265,563,039.84, representing 8.05% of total assets, reflecting a decline of 5.01% compared to the previous year[68]. - Fixed assets totaled ¥495,386,136.35, making up 15.01% of total assets, down by 2.63% year-over-year[69]. - Short-term borrowings increased significantly to ¥228,805,644.52, which is 6.93% of total assets, marking a 99.36% increase from the previous year[69]. - The total liabilities as of June 30, 2022, were CNY 1,544,986,253.01, slightly down from CNY 1,551,197,088.41 at the beginning of the year[140]. Market and Industry Insights - The global market for massage equipment exceeded $15 billion in 2019, with China becoming the fastest-growing region for demand[28]. - The market size of China's massage appliance industry was 8.75 billion yuan in 2021, projected to reach 15.27 billion yuan by 2026[28]. - The massage equipment industry is expected to grow significantly due to increasing health awareness and the aging population in China[28]. - The company focuses on the design, R&D, production, and sales of massage equipment, aiming to provide a healthy lifestyle for global users[32]. - The company operates under a multi-channel sales model, including direct sales, e-commerce, and ODM for international markets[36]. - The company’s main products include full-function massage chairs and portable massage devices, catering to various user needs[32]. - The company emphasizes the integration of traditional Chinese medicine with modern technology in its product development[26]. Strategic Initiatives - The company aims to optimize internal management and strengthen product segmentation to adapt to market challenges and maintain its industry position[47]. - The company plans to focus on market expansion and new product development in the upcoming quarters[139]. - The company has initiated a strategic acquisition plan, targeting companies that align with its growth objectives, with a budget of 200,000 million for potential acquisitions[162]. - The company has actively expanded its online presence, particularly in the low-price segment, and has engaged in live-streaming sales to enhance brand visibility[53]. - The company launched new high-end products, including the M810 and M880 series, aimed at enhancing brand image and increasing market share in the premium segment[56]. Risks and Challenges - The company has outlined potential risks in its management discussion and analysis section, advising investors to be cautious[9]. - The company faces risks related to fluctuations in raw material prices, which could directly impact product costs and profitability[85]. - Increased competition in the massage equipment market has led to a focus on brand reputation and product functionality, with the company planning to enhance R&D investment to maintain technological leadership[89]. - The company primarily settles its export business in USD, exposing it to foreign exchange risks, which it aims to mitigate through various strategies including RMB settlement and hedging tools[88]. Corporate Governance and Compliance - The company has no significant litigation or arbitration matters during the reporting period[103]. - The company has fulfilled all commitments related to its initial public offering and refinancing[100]. - The company has maintained good integrity status, with no overdue debts or unfulfilled court judgments[103]. - The company has established a dedicated account for the management of the raised funds, in compliance with regulatory requirements[124]. - The company has confirmed that there are no significant doubts regarding its ability to continue as a going concern for the next 12 months[181].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,101,358,555.51, a decrease of 11.78% compared to CNY 1,248,377,561.46 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was CNY 86,367,502.94, down 38.47% from CNY 140,366,552.96 in the previous year[21]. - The net cash flow from operating activities decreased by 47.64% to CNY 98,446,913.62, compared to CNY 188,022,479.97 in the same period last year[21]. - Basic earnings per share for the first half of 2022 were CNY 0.65, a decline of 36.89% from CNY 1.03 in the previous year[22]. - The weighted average return on net assets decreased to 4.78%, down 3.48 percentage points from 8.26% in the same period last year[22]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was CNY 79,921,203.93, down 28.37% from CNY 111,575,789.90 in the previous year[21]. - The company reported a significant increase in management expenses by 35.69% to approximately ¥45.73 million, attributed to increased share-based payments[65]. - The company reported a decrease in cash inflow from sales of goods and services, totaling ¥1,177,314,300.83, down 12.1% from ¥1,339,312,132.36 in the previous year[149]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,300,276,316.39, an increase of 0.68% from CNY 3,277,932,920.71 at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were CNY 1,774,162,416.72, a slight decrease of 0.12% from CNY 1,776,370,370.24 at the end of the previous year[21]. - Cash and cash equivalents at the end of the period reached ¥1,161,888,674.51, representing 35.21% of total assets, an increase of 4.75% year-over-year[68]. - Accounts receivable amounted to ¥147,652,941.81, accounting for 4.47% of total assets, with a year-over-year increase of 3.50%[68]. - Inventory decreased to ¥265,563,039.84, representing 8.05% of total assets, reflecting a decline of 5.01% compared to the previous year[68]. - Fixed assets totaled ¥495,386,136.35, making up 15.01% of total assets, down by 2.63% year-over-year[69]. - Short-term borrowings increased significantly to ¥228,805,644.52, which is 6.93% of total assets, marking a 99.36% increase from the previous year[69]. - The total liabilities of the company were reported at 3,776,100,000, indicating a slight increase from the previous year's 3,370,240,000[156]. Market and Industry Insights - The massage appliance industry has seen a global market size expansion, surpassing $10 billion in 2015 and $15 billion in 2019, with China's market expected to grow from 8.75 billion yuan in 2021 to 15.27 billion yuan by 2026[28]. - The company focuses on the design, research and development, production, and sales of massage appliances, aiming to provide a healthy lifestyle for global users[32]. - The company operates under a multi-channel sales model, including direct sales, e-commerce, and experience stores in the domestic market, while primarily using ODM for international markets[36]. - The company is positioned in a high-marketization industry, with significant export proportions and a focus on consumer health awareness[25]. - The massage appliance industry is expected to benefit from increasing health consciousness and the aging population, making it a promising market[30]. Strategic Initiatives - The company has a dual-brand strategy with "Rongtai" targeting the high-end market and "Momo Da" focusing on entry-level products, covering various consumer segments[49]. - The company has actively participated in the development of 17 industry standards, including 4 national standards, demonstrating its commitment to industry leadership[43]. - The company aims to strengthen its market position by focusing on innovation, technology, and cost reduction strategies amid external challenges[47]. - The company has launched multiple interactive initiatives with brand ambassador Wang Yibo to enhance brand engagement and drive sales[50]. - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming quarters[159]. Research and Development - The company invested approximately ¥119 million in R&D, accounting for 4.56% of its total revenue, maintaining a consistent R&D investment ratio around 5% over the years[62]. - The company has allocated 44,459 million for research and development to enhance its technological capabilities[162]. - The company's research and development expenses for the first half of 2022 were CNY 45,671,497.44, down 21.6% from CNY 58,316,138.26 in the same period of 2021[142]. Risks and Challenges - The company faces risks related to fluctuations in raw material prices, which could directly impact product costs and profitability[85]. - The company is implementing domestic chip production and alternative parts strategies to mitigate risks associated with raw material price volatility[85]. - Increased competition in the massage equipment market has led to a focus on brand reputation and product functionality, with the company planning to enhance R&D investment to maintain technological leadership[89]. - The company primarily settles its export business in USD, exposing it to foreign exchange risks, which it aims to mitigate through various strategies including RMB settlement and hedging tools[88]. Shareholder and Equity Information - The total number of shares increased by 30,000, resulting in a total of 140,003,402 shares[114]. - The top three shareholders hold a combined total of 76.43% of the company's shares, with Lin Qi holding 28.93%, Lin Guangrong 18.36%, and Lin Jue 7.14%[120]. - The company has a total of 10,214 common stock shareholders as of the end of the reporting period[118]. - The company has established a dedicated account for the management of repurchased shares, holding 3,348,479 shares, which is 2.39% of the total shares[121]. Compliance and Governance - The company has no significant litigation or arbitration matters during the reporting period[103]. - The company has fulfilled all commitments related to its initial public offering and refinancing[100]. - The company has maintained good integrity status, with no unfulfilled court judgments or significant overdue debts[103]. - The financial statements are prepared based on the going concern assumption, with no significant doubts regarding the company's ability to continue operations for the next 12 months[181].

Financial Performance - The company's operating revenue for Q1 2022 was ¥564,797,326.35, representing an increase of 8.55% compared to the same period last year[5]. - The net profit attributable to shareholders decreased by 15.02% to ¥58,326,127.42[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 30.38% to ¥42,769,318.58, primarily due to a decline in gross margin[8]. - Net profit for Q1 2022 was ¥58,563,444.46, a decrease of 15.2% from ¥69,039,012.93 in Q1 2021[18]. - Total comprehensive income for Q1 2022 was CNY 58,341,010.73, a decrease from CNY 69,014,207.63 in Q1 2021[19]. - Basic earnings per share for Q1 2022 was CNY 0.44, down from CNY 0.50 in Q1 2021[19]. - The basic earnings per share for the period was ¥0.44, down by 12.00%[5]. - The diluted earnings per share was ¥0.42, a decrease of 12.50%[5]. - The weighted average return on equity was 3.23%, a decrease of 0.83 percentage points[5]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥27,415,890.24, a decrease of 146.53% compared to the previous year, mainly due to increased payments for purchased goods[8]. - Net cash flow from operating activities for Q1 2022 was negative CNY 27,415,890.24, compared to positive CNY 58,917,339.02 in Q1 2021[22]. - Cash inflow from operating activities totaled CNY 630,228,464.99 in Q1 2022, down from CNY 678,974,675.65 in Q1 2021[21]. - Cash outflow from operating activities increased to CNY 657,644,355.23 in Q1 2022, compared to CNY 620,057,336.63 in Q1 2021[22]. - Net cash flow from investing activities was CNY 70,058,635.23 in Q1 2022, a significant improvement from negative CNY 181,340,777.02 in Q1 2021[22]. - Cash inflow from financing activities was CNY 134,720,427.86 in Q1 2022, with net cash flow from financing activities of CNY 133,206,273.40[22]. - Cash and cash equivalents increased to ¥1,284,376,555.91 from ¥1,109,244,715.14 at the end of 2021, reflecting a growth of 15.8%[14]. - Cash and cash equivalents at the end of Q1 2022 were CNY 1,284,376,555.91, up from CNY 760,845,363.07 at the end of Q1 2021[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,370,609,904.10, an increase of 2.83% from the end of the previous year[6]. - The company's total assets as of March 31, 2022, amounted to ¥3,370,609,904.10, an increase from ¥3,277,932,920.71 at the end of 2021[14]. - Current assets totaled ¥2,131,739,325.31, slightly up from ¥2,038,261,461.70 at the end of 2021[14]. - Total liabilities increased to ¥1,528,376,484.16 from ¥1,497,786,372.69 at the end of 2021, marking a rise of 2.7%[15]. - The equity attributable to shareholders increased by 3.48% to ¥1,838,231,565.13[6]. - The equity attributable to shareholders rose to ¥1,838,231,565.13 from ¥1,776,370,370.24 at the end of 2021, an increase of 3.5%[15]. Shareholder Information - The company had a total of 9,277 common shareholders at the end of the reporting period[10]. Research and Development - The company reported a decrease in research and development expenses to ¥25,166,930.13 from ¥26,331,939.12 in Q1 2021, a decline of 4.4%[18]. Financial Expenses - The company’s financial expenses included interest expenses of ¥8,056,346.77, up from ¥7,034,346.26 in Q1 2021[18].